Royalty Pharma (MEX:RPRX) Accounts Payable & Accrued Expense : MXN3,389 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Accounts Payable & Accrued Expense?

Royalty Pharma's quarterly accounts payable & accrued expense increased from Sep. 2024 (MXN2,749 Mil) to Dec. 2024 (MXN3,905 Mil) but then declined from Dec. 2024 (MXN3,905 Mil) to Mar. 2025 (MXN3,389 Mil).

Royalty Pharma's annual accounts payable & accrued expense declined from Dec. 2022 (MXN3,058 Mil) to Dec. 2023 (MXN2,546 Mil) but then increased from Dec. 2023 (MXN2,546 Mil) to Dec. 2024 (MXN3,905 Mil).

Royalty Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Royalty Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Accounts Payable & Accrued Expense Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5,754.50

3,513.02

3,058.36

2,546.17

3,905.08

Royalty Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1,917.78	3,264.79	2,749.08	3,905.08	3,388.84

Royalty Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.